ALCAR.PA Stock Bounces at €0.099 on EURONEXT After 91% YTD Decline

Carmat SA (ALCAR.PA) trades at €0.099 on EURONEXT as of market close on May 6, 2026. The French medical device maker has endured a brutal year, with ALCAR.PA stock down 91% year-to-date. Despite the steep decline, technical signals suggest an oversold bounce may be underway. The company designs total artificial hearts for end-stage heart failure patients. With 807,348 shares trading today, volume remains elevated relative to the 50-day average. Meyka AI’s analysis reveals mixed fundamentals beneath the surface.

ALCAR.PA Stock Price Action and Technical Setup

Carmat SA stock hit €0.099 at market close, unchanged from the previous session. The day’s range spanned €0.097 to €0.11, showing tight consolidation near support levels. Year-to-date, ALCAR.PA has collapsed 91%, while the 52-week high sits at €1.51 versus a low of €0.085. The stock trades well below both its 50-day average of €0.1475 and 200-day average of €0.5947, confirming a severe downtrend.

Volume activity provides a glimmer of hope. Today’s 807,348 shares traded slightly above the 797,166 average, suggesting renewed interest at depressed levels. The Keltner Channels show the stock hovering near the middle band at €0.10, indicating potential consolidation before the next move. Money Flow Index sits at 50, neutral territory that could precede directional momentum.

Carmat SA Fundamentals: Profitability Crisis and Debt Burden

Carmat SA faces severe profitability headwinds that explain the stock’s collapse. The company posted negative earnings per share of €-1.15, with a net profit margin of negative 7.34%. Operating margins stand at negative 7.03%, showing the business burns cash on every euro of revenue. Free cash flow per share reached €-1.97, confirming ongoing cash burn.

Debt metrics paint an alarming picture. The debt-to-equity ratio sits at negative 1.13, while debt-to-assets reached 1.36, indicating liabilities exceed total assets. Interest coverage of negative 15.38 means the company cannot service debt from operations. Working capital of €13.28 million provides minimal cushion. Track ALCAR.PA on Meyka for real-time updates on cash burn trends and financing developments.

Market Sentiment: Trading Activity and Liquidation Pressure

Trading Activity shows mixed signals as ALCAR.PA consolidates near support. The relative volume of 1.01x suggests institutional interest remains muted despite the oversold condition. The stock’s 93% decline from its €1.51 peak has likely triggered forced selling from underwater positions. However, the tight daily range indicates buyers are defending the €0.097 support level.

Liquidation Pressure appears to be easing after the initial capitulation. The market cap of €6.36 million is microscopic, limiting institutional participation. Retail traders dominate the order flow at these penny-stock levels. The Relative Vigor Index at 50 suggests neither buyers nor sellers control momentum, creating potential for a relief bounce if sentiment shifts.

Financial Metrics and Valuation Reality Check

Carmat SA’s valuation metrics are distorted by negative earnings, making traditional ratios unreliable. The price-to-sales ratio of 0.91 appears cheap, but revenue of only €0.31 per share limits growth potential. The enterprise value of €59.46 million dwarfs the market cap, reflecting substantial debt. Return on equity of 1.07% shows the company destroys shareholder value.

The company’s financial growth shows modest revenue expansion of 1.46% year-over-year, but this masks underlying operational stress. Operating cash flow declined sharply, with negative €1.90 per share. The current ratio of 1.70 suggests adequate short-term liquidity, but this deteriorates rapidly if cash burn continues. Meyka AI rates ALCAR.PA with a grade of B, suggesting a hold stance despite the oversold technicals. This grade factors in sector performance, financial metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Carmat SA (ALCAR.PA) presents a classic oversold bounce setup at €0.099, but fundamental weakness remains the dominant theme. The 91% year-to-date decline has pushed the stock into deeply depressed territory, attracting bargain hunters. However, negative earnings, cash burn, and debt burden suggest the decline may have further to run. The medical device sector on EURONEXT shows resilience, but Carmat’s execution challenges isolate it from sector strength. Volume uptick and technical consolidation offer short-term bounce potential, yet investors should demand clarity on path to profitability before committing capital. The oversold condition is real, but so is the business crisis.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.